Syndax Pharmaceuticals Inc (NASDAQ:SNDX) does about 2.29M shares in volume on a normal day but saw 3025441 shares change hands in the recent trading day. The company now has a market cap of 944.80M USD. Its current market price is $10.98, marking an increase of 4.17% compared to the previous close of $10.54. The 52 week high reached by this stock is $25.07 whilst the lowest price level in 52 weeks is $8.58. The script in recent trading has seen the stock touch a high of $41 and a low of $18.
4 analysts observing the Syndax Pharmaceuticals Inc (SNDX) stock have set the 12-month price targets for the company’s shares at between $18 and $41. The consensus objective for the share price is $35.58, suggesting that the stock has a potential upside of 69.14% over the period. The median price target is 69.07% away from the current levels at $35.5.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 24, 2024 when UBS initiated the stock to “Buy” and issued a price target of $37. Scotiabank downgraded its price target at $36-$23.
The current price level is 5.71%, -5.78%, and -28.46% away from its SMA20, SMA50, and SMA200 respectively, with the SNDX price moving above the 50-day SMA on current market day. Syndax Pharmaceuticals Inc (SNDX) stock is up 11.47% over the week and -20.55% over the past month. Its price is -16.94% year-to-date and -44.32% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.99 and -3.71 for whole year. Expected sales for next quarter are $33.46M, which analysts say will come at $123.66M for the current fiscal year and next year at $265.37M. In addition, estimates put the company’s current quarterly revenue at an average of $27.01M.
Its 12-month price target is $35.5. To reach the target analysts have set, the stock logically needs to grow 69.14 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $18, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $41.
Outstanding shares total 86.05M with insiders holding 1.30% of the shares and institutional holders owning 120.65% of the company’s common stock. The company has a return on investment of -60.64% and return on equity of -93.70%. The beta has a value of 0.74. Price to book ratio is 4.39 and price to sales ratio is 21.61.
